{"entity":{"id":"nct06292208","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of IBD0333 in advanced solid tumours, run by SUNHO（China）BioPharmaceutical CO., Ltd., now recruiting.","summary":"A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT06292208 by SUNHO（China）BioPharmaceutical CO., Ltd., with 48 participants planned, started 2024-03-09 and due to reach its primary completion in 2029-12-31. Interventions recorded: IBD0333.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06292208","url":"https://clinicaltrials.gov/study/NCT06292208"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06292208","phase":"1/2","setting":"Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) and Preliminary Efficacy of IBD0333 in Patients With Locally Advanced/Metastatic Solid Tumor or Non-Hodgkin Lymphoma","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","enrolled":48,"outcomes":[]},"route":"/trials/nct06292208/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}